Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 22, 2015, Pages 6979-6984

  La, Jennifer ^a,b   Latham, Catherine F ^a   Tinetti, Ricky N ^a,b   Johnson, Adam ^a   Tyssen, David ^a   Huber, Kelly D ^c   Sluis Cremer, Nicolas ^c   Simpson, Jamie S ^b   Headey, Stephen J ^b   Chalmers, David K ^b   Tachedjian, Gilda ^a,b,d  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Allosteric inhibitors; Fragment based drug discovery; HIV; Reverse transcriptase; STD NMR

Indexed keywords

4 AMINOPHENOL; 4 DIMETHYLAMINO 6 VINYLPYRIMIDINE 1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED DNA POLYMERASE BETA; DNA DIRECTED DNA POLYMERASE GAMMA; INDOLOPYRIDONE 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRIMER DNA; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; PRODRUG;

ARTICLE; CONTROLLED STUDY; DNA TEMPLATE; DRUG DOSE INCREASE; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME INACTIVATION; ENZYME INHIBITION; ESCHERICHIA COLI; IN VITRO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STEADY STATE; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GEL MOBILITY SHIFT ASSAY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLONEY MURINE LEUKEMIA VIRUS;

DNA PRIMERS; DRUG DISCOVERY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HIV-1; MAGNETIC RESONANCE SPECTROSCOPY; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

EID: 84930958949     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423900112     Document Type: Article

References (37)

1. UNAIDS (2013) UNAIDS report on the global AIDS epidemic 2013. Available at www.unaids.org/sites/default/files/media-asset/UNAIDS-Global-Report-2013-en-1.pdf. Accessed May 5, 2015.
2. Tsibris AM, Hirsch MS (2010) Antiretroviral therapy in the clinic. J Virol 84(11):5458-5464.
3. Gupta RK, et al. (2013) Oral antiretroviral drugs as public health tools for HIV prevention: Global implications for adherence, drug resistance, and the success of HIV treatment programs. J Infect Dis 207(Suppl 2):S101-S106.
4. Esposito F, Corona A, Tramontano E (2012) HIV-1 reverse transcriptase still remains a new drug target: Structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions. Mol Biol Int 2012:586401.
5. Bahar I, Erman B, Jernigan RL, Atilgan AR, Covell DG (1999) Collective motions in HIV-1 reverse transcriptase: Examination of flexibility and enzyme function. J Mol Biol 285(3): 1023-1037.
6. Bauman JD, et al. (2013) Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening. J Med Chem 56(7):2738-2746.
7. Freisz S, et al. (2010) Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action. Angew Chem Int Ed Engl 49(10):1805-1808.
8. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: Strategic advances and lessons learned. Nat Rev Drug Discov 6(3):211-219.
9. Tsai J, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105(8):3041-3046.
10. Congreve M, Carr R, Murray C, Jhoti H (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8(19):876-877.
11. Meiby E, et al. (2013) Fragment screening by weak affinity chromatography: Comparison with established techniques for screening against HSP90. Anal Chem 85(14):6756-6766.
12. Silvestre HL, Blundell TL, Abell C, Ciulli A (2013) Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc Natl Acad Sci USA 110(32):12984-12989.
13. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: A useful metric for lead selection. Drug Discov Today 9(10):430-431.
14. Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10(7):464-469.
15. Sheen CW, Alptürk O, Sluis-Cremer N (2014) Novel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action. Biochem J 462(3):425-432.
16. Geitmann M, et al. (2011) Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. J Med Chem 54(3):699-708.
17. Wielens J, et al. (2013) Parallel screening of low molecular weight fragment libraries: Do differences in methodology affect hit identification? J Biomol Screen 18(2):147-159.
18. Bauman JD, et al. (2008) Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res 36(15):5083-5092.
19. Rajotte D, et al. (2013) Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series. Antimicrob Agents Chemother 57(6): 2712-2718.
20. Maga G, et al. (2007) Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate. Angew Chem Int Ed Engl 46(11): 1810-1813.
21. Wensing AM, et al. (2014) 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 22(3):642-650.
22. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55(1): 170-171.
23. Jochmans D, et al. (2006) Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J Virol 80(24):12283-12292.
24. Yuasa S, et al. (1993) Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol Pharmacol 44(4):895-900.
25. Dalvit C (2009) NMR methods in fragment screening: Theory and a comparison with other biophysical techniques. Drug Discov Today 14(21-22):1051-1057.
26. Borkow G, et al. (1997) Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 36(11):3179-3185.
27. Felts AK, et al. (2011) Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies. J Chem Inf Model 51(8):1986-1998.
28. Yamazaki S, et al. (2007) Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem Biol 14(7):804-812.
29. Wang LZ, Kenyon GL, Johnson KA (2004) Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1. J Biol Chem 279(37): 38424-38432.
30. Baell JB, Ferrins L, Falk H, Nikolakopoulos G (2013) PAINS: Relevance to tool compound discovery and fragment-based screening. Aust J Chem 66(12):1483-1494.
31. Coté ML, Roth MJ (2008) Murine leukemia virus reverse transcriptase: Structural comparison with HIV-1 reverse transcriptase. Virus Res 134(1-2):186-202.
32. Bec G, et al. (2013) Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors. J Am Chem Soc 135(26): 9743-9752.
33. Schauer GD, Huber KD, Leuba SH, Sluis-Cremer N (2014) Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. Nucleic Acids Res 42(18):11687-11696.
34. Yap SH, et al. (2007) N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 4(12):e335.
35. Hill AV (1910) The possible effect of the aggregation of the molecules of haemoglobin on its oxygen dissociation curve. J Physiol 40:iv-vii.
36. Radzio J, Sluis-Cremer N (2008) Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol 73(2):601-606.
37. Parniak MA, Min KL, Budihas SR, Le Grice SF, Beutler JA (2003) A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal Biochem 322(1):33-39.